Kate Flavin McKinley

Kate Flavin McKinley has held a variety of roles in the pharmaceutical industry since 2000. Kate began their career as a Sales Representative for AbbVie's Endocrine Franchise and advanced to a Regional Sales Trainer. Kate then moved to the Cardiovascular Franchise, where they held the roles of Regional Sales Director, Area Training Manager, Senior District Manager, and District Manager. In 2017, they joined Dendreon as Vice President of Marketing, Training, and Hospital Channel for the Urology and Oncology Franchise. In 2019, they became Chief Executive Officer and Chief Commercial Officer of Elevar Therapeutics, a pharmaceutical startup specializing in the clinical development of oncology therapies. In 2021, they joined the Board of Directors of Hainan Pactil Advanced Therapeutics Company LTD. Currently, they serve as Board Director and Chair of the Investment Committee for Maxwell Biosciences, as well as Strategic Advisor for Imagene AI and Derma Corporation.

Kate Flavin McKinley has obtained a Certificate in Corporate Governance from Wharton Executive Education, a Master of Business Administration - MBA in Marketing Strategy from The University of Tulsa: Collins College of Business, and a B.S.B.A. in Marketing & Management with a Minor in Psychology from The University of Tulsa. Additionally, they have obtained certifications from Women In Bio - Engage. Educate. Empower., Wharton Executive Education, National Comprehensive Cancer Network\u00ae (NCCN\u00ae), Gartner, TIGNUM GMBH, The American Academy of Anti-Aging Medicine (A4M), Beta Gamma Sigma, Joslin Diabetes Center, Harvard University, and Endocrinology, Diabetes & Metabolism Certification.